MarketCapExport financials
CureVac N.V. (CVAC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
CureVac N.V. Cash Flow 2024-2011 | CVAC
Brief overview of CureVac N.V.'s cash movements
Cash flows are assessed across five available annual periods spanning 2020 to 2024.
Core cash generation deteriorated, ending at €101.9 million versus €522.4 million at the beginning.
Only 2 of five annual observations were positive, indicating weak repeatability.
Overall picture
Taken together, CureVac N.V.'s cash flow indicators point to increased dependence on reserves or outside financing.
Annual Cash Flow CureVac N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
102 M | -268 M | -286 M | -733 M | 522 M | -87 M | -74.1 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Quarterly Cash Flow CureVac N.V.
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-83.4 M | -41.4 M | 102 M | 168 M | -186 M | -96.6 M | -268 M | -224 M | -164 M | -99.6 M | -286 M | - | - | -137 M | - | - | - | -197 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Cash Flow Statement is one of the three key financial reports of the company CureVac N.V., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Ocugen
OCGN
|
$ 0.78 | 0.06 % | $ 244 M |  USA |
 |
Oragenics
OGEN
|
$ 0.43 | 1.69 % | $ 928 K | USA |
 |
Omeros Corporation
OMER
|
$ 16.2 | 1.95 % | $ 1.03 B | USA |
 |
ORIC Pharmaceuticals
ORIC
|
$ 12.35 | 10.18 % | $ 1.08 B | USA |
 |
Aligos Therapeutics
ALGS
|
$ 4.86 | 3.06 % | $ 48 M | USA |
 |
Alkermes plc
ALKS
|
$ 41.22 | 2.79 % | $ 6.79 B |  Irlanda |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 210.23 | 2.28 % | $ 12.8 B | Irlanda |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.87 | 0.05 % | $ 5.21 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 104.78 | 1.23 % | $ 8.85 B | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 241.76 | 3.86 % | $ 5.44 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | 0.34 % | $ 138 M |  Niderland |
 |
PTC Therapeutics
PTCT
|
$ 59.24 | 2.21 % | $ 4.71 B | USA |
 |
Arcus Biosciences
RCUS
|
$ 22.12 | 1.26 % | $ 2.38 B | USA |
 |
Larimar Therapeutics
LRMR
|
$ 1.99 | 1.51 % | $ 165 M | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 790.74 | 0.01 % | $ 82.7 B | USA |
 |
Rafael Holdings
RFL
|
$ 1.39 | 2.8 % | $ 40.9 M | USA |
 |
REGENXBIO
RGNX
|
$ 6.93 | 4.07 % | $ 357 M | USA |
 |
Royalty Pharma plc
RPRX
|
$ 60.96 | 2.25 % | $ 26.2 B | USA |
 |
Seer
SEER
|
$ 2.03 | 0.44 % | $ 112 M | USA |
 |
PDS Biotechnology Corporation
PDSB
|
$ 1.13 | 0.62 % | $ 52.4 M | USA |
 |
SIGA Technologies
SIGA
|
$ 3.17 | 0.16 % | $ 227 M | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 21.3 | 4.46 % | $ 1.02 T |  France |
 |
Syndax Pharmaceuticals
SNDX
|
$ 12.9 | 0.89 % | $ 1.12 B | USA |
 |
Soligenix
SNGX
|
$ 0.35 | 1.67 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.42 | 0.71 % | $ 1.24 B | USA |
|
Nuvation Bio
NUVB
|
$ 4.45 | 1.6 % | $ 1.52 B | USA |
 |
Sarepta Therapeutics
SRPT
|
$ 17.1 | 0.03 % | $ 1.71 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.69 | 0.6 % | $ 2.21 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
$ 0.48 | 0.2 % | $ 5.91 B |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
$ 9.98 | 4.02 % | $ 1.09 B | USA |
|
Protara Therapeutics
TARA
|
$ 2.32 | 1.46 % | $ 99.4 M | USA |
 |
Relay Therapeutics
RLAY
|
$ 16.28 | 1.41 % | $ 2.79 B | USA |
 |
Pfizer
PFE
|
$ 29.58 | 0.54 % | $ 168 B | USA |
 |
Supernus Pharmaceuticals
SUPN
|
$ 37.88 | 0.5 % | $ 2.14 B | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 19.67 | 1.08 % | $ 31.1 B |  Japan |
 |
Revolution Medicines
RVMD
|
$ 177.96 | 0.22 % | $ 33.8 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
$ 86.17 | 0.6 % | $ 5.6 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.26 | 0.9 % | $ 251 M | USA |
 |
Sana Biotechnology
SANA
|
$ 2.27 | 6.22 % | $ 575 M | USA |
 |
Pulmatrix
PULM
|
$ 1.36 | 4.61 % | $ 4.97 B | USA |
 |
Zoetis
ZTS
|
$ 79.38 | 1.22 % | $ 35.2 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 14.54 | 1.81 % | $ 1.43 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.96 | 2.62 % | $ 1.32 B | Israel |
 |
Zymeworks
ZYME
|
$ 25.03 | 0.16 % | $ 1.29 B |  Canada |
 |
AC Immune SA
ACIU
|
$ 2.39 | 2.08 % | $ 241 M |  Schweiz |
 |
Adagene
ADAG
|
$ 2.06 | 4.8 % | $ 122 M |  China |
 |
Adial Pharmaceuticals
ADIL
|
$ 3.49 | 11.15 % | $ 2.33 M | USA |
 |
ADC Therapeutics SA
ADCT
|
$ 1.4 | 0.34 % | $ 178 M | Schweiz |